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DOI 10.1016/j.ccr.2011.07.017SUMMARYBreast cancer initiating cells (BCICs), which can fully recapitulate the tumor origin and are often resistant to
chemo- and radiotherapy, are currently considered as amajor obstacle for breast cancer treatment. Here, we
show that BIKDD, a constitutively active mutant form of proapoptotic gene, BIK, effectively induces
apoptosis of breast cancer cells and synergizes with lapatinib. Most importantly, BikDD significantly reduces
BCICs through co-antagonism of its binding partners Bcl-2, Bcl-xL, and Mcl-1, suggesting a potential
therapeutic strategy targeting BCICs. Furthermore, we developed a cancer-specific targeting approach for
breast cancer that selectively expresses BikDD in breast cancer cells including BCICs, and demonstrated
its potent antitumor activity and synergism with lapatinib in vitro and in vivo.INTRODUCTION
Cancer initiating cells (CICs), also termed cancer stem cells, are
a small subpopulation of cancer cells within tumors with charac-
teristics of resistance to cancer treatments and regrowth of new
tumors, and are currently considered as a major obstacle for
cancer therapies (Gupta et al., 2009; Li et al., 2008; Park et al.,
2009; Yu et al., 2007). Breast cancer initiating cells (BCICs)
was identified in an enriched CD44+/CD24 subfraction of cells,
can form mammospheres in suspension culture, and are often
resistant to chemo- and radiotherapy (Al-Hajj et al., 2003; Dontu
et al., 2003; Li et al., 2008; Yu et al., 2007). Although lapatinib has
been shown to be able to stabilize this small population of BCICsSignificance
The Bcl-2 family of proteins is essential for tumorigenesis and
this study, we uncovered an important role of Bcl-2 antiapopt
redundancy of Bcl-2 antiapoptotic proteins, coinhibition of the
tize breast cancer cells to lapatinib. We also demonstrated tha
proapoptotic partner, BikDD, through an expression vector se
and synergized with lapatinib in animal models. Taken togeth
of future clinical trials, with extra benefit for breast cancer pat
Canin the clinic (Li et al., 2008), there are no drugs currently available
that can effectively reduce BCICs in patients. Moreover, due to
the resistant nature of BCICs to chemo- and radiotherapy, treat-
ments using these conventional methods have been shown to
increase the BCIC population from 9% to 74% in tumors of the
treated patients, and the loss of responsiveness of BCICs to
these treatments will eventually lead to tumor relapse (Li et al.,
2008; Yu et al., 2007). Therefore, it is imperative to develop anti-
cancer drugs targeting BCICs.
One key mechanism that accounts for chemoresistance in
cancer initiating cells is low susceptibility to apoptosis (Park
et al., 2009). For example, evasion of apoptosis through deregu-
lated mitochondrial apoptosis machinery is essential for tumordevelopment of resistance to chemotherapies. However, in
otic proteins in the survival of BCICs. Due to the functional
se proteins is required to optimally reduce BCICs and sensi-
t inactivation of multiple Bcl-2 antiapoptotic proteins by their
lective for breast cancer produced a profound killing effect
er, the current study provides a therapeutic strategy worthy
ients by triggering apoptosis in BCICs.
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Figure 1. BikDD Effectively Reduces the CD44+/CD24– Population and Mammosphere Formation of Breast Cancer Cells
(A) MDA-MB-468 cells were infected with lentivirus containing BIKDD or vector alone, and were analyzed by cell numbers, MTT and clonogenicity assays (setting
at 100% in vector group).
(B) Cells were imaged, and were immunoblotted by N-terminal Bik antibody and cleaved PARP antibody, respectively. Scale bar represents 10 mm.
(C) 200,000 MDA-MB-468 cells were analyzed by flow cytometry 7 days post infection or paclitaxel treatment once at 1.0 mg/ml dose using fluorescent-
conjugated CD44 and CD24 antibodies. The data represent the mean of three independent experiments. For mammosphere formation assay, 3000 cells were
used, and mammospheres were counted under microscope with sizeR100 mm.
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BikDD Kills Breast Cancer Initiating Cellsinitiation and progression, enabling cancer cells to undergo
unchecked proliferation, maintain survival, and acquire drug
resistance (Datta et al., 1999; Fesik, 2005; Hanahan and Wein-
berg, 2000; McCubrey et al., 2006; Mills et al., 2008). The Bcl-2
family is the primary regulator of the mitochondrial apoptosis
pathway and is classified into three subgroups according to
their Bcl-2 homology (BH) domains: the multidomain antiapop-
totic subgroup (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bfl-1/A1), the multi-
domain proapoptotic subgroup (Bax, Bak), and the BH3-only
proapoptotic subgroup (Bid, Bim, Bad, Bik, Noxa, Puma, Bmf,
Hrk) (Certo et al., 2006). An intricate balance of members within
these three subgroups of Bcl-2 family determines the outcome
of death signals. Interestingly, several reports have indicated
that Bcl-2 and Bcl-xL, which are antiapoptotic members of
the Bcl-2 family, may be involved in the survival of leukemia
and glioblastoma cancer initiating cells (Domen and Weissman,
2000; Konopleva et al., 2006; Liu et al., 2006).
Unlike normal cells, expression of proapoptotic members and
their antiapoptotic counterparts are oftenmismatched to bypass
apoptosis in breast cancer cells. For instance, Bcl-2, Bcl-xL, and
Mcl-1 are overexpressed in breast cancer cells that is correlated
with high tumor grade and poor prognosis of breast cancer
patients (Ding et al., 2007; Hamilton and Piccart, 2000; Olopade
et al., 1997; Silvestrini et al., 1994). In addition, overexpression of
Bcl-2, Bcl-xL, and/or Mcl-1 has also been implicated in the
development of drug resistance in the clinic after chemotherapy
such as paclitaxel, doxorubicin, cisplatin, and bortezomib (Bauer
et al., 2005; Ellis et al., 1998; Gomez-Bougie et al., 2007; Olters-
dorf et al., 2005; Tabuchi et al., 2009; Teixeira et al., 1995; van
Delft et al., 2006). Because the overall expression pattern of
Bcl-2, Bcl-xL, and Mcl-1 appears to inversely correlate with
apoptotic response following drug treatment, an antagonist
that targets all of these antiapoptotic proteins would be ex-
pected to have the greatest proapoptotic efficacy and a broader
and more effective application in different breast cancer cells.
However, it is not yet clear whether this approach will be appli-
cable to BCICs, which are a major determinant for tumor recur-
rence due to their resistant nature to traditional therapies.
Lapatinib, a dual EGFR/HER2 small molecule tyrosine kinase
inhibitor, is one of the drugs currently used in the clinic for
treating HER2-positive breast cancer patients, which stabilizes
but does not reduce the BCIC population in patients (Geyer
et al., 2006; Li et al., 2008). To achieve their clinical efficacy,
anti-HER2 drugs such as trastuzumab and lapatinib greatly
depend on their ability to promote apoptosis in cancer cells
through HER2 inhibition. For instance, despite inhibition of
p-EGFR, p-HER2, p-Erk1/2, and p-Akt, an inoperative apoptosis
machinery renders breast cancer cells ineffective to trastuzumab
or lapatinib-induced apoptosis (Burris et al., 2005; Mohsin et al.,
2005). The acquired resistance of breast cancer cells to lapatinib
has been attributed to overexpression of Bcl-2 and Mcl-1, sug-
gesting that lapatinib-induced apoptosis requires inactivation
of antiapoptotic Bcl-2 family proteins (Martin et al., 2008; Xia
et al., 2006).(D) MDA-MB-468 mammospheres established above were infected with lentiv
mammospheres were counted within 7 days. Scale bar represents 50 mm.
(E) BT474 cells eliminated the CD44+/CD24 population and mammosphere form
CanTo develop a therapeutic approach that can promote
apoptosis in breast cancer including BCICs and enhance treat-
ment efficacy of lapatinib, we used a mutant form of BH3-only
proapoptotic protein Bik (BikDD), in which the mutations T33D
and S35Dweremade tomimic the constitutively phosphorylated
form with enhanced binding affinity to its multiple binding part-
ners Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 (Chen et al., 2004; Day
et al., 2006; Li et al., 2003; Xie et al., 2007; Zou et al., 2002).
We first examined the role of BikDD targeting BCICs compared
to individual knockdown or co-silencing of Bcl-2, Bcl-xL, and
Mcl-1 using shRNAs. Further, we examined the therapeutic
effect of BikDD driven by engineered breast cancer-selective
promoter and in combination with lapatinib in breast cancer
cells, including BCICs.
RESULTS
BikDD Effectively Induces Apoptosis in Breast Cancer
Cells and Reduces the CD44+/CD24– Population,
Mammosphere Formation, and Cancer Initiation Activity
To examine the proapoptotic effect of BikDD, a potent mutant
form of the proapoptotic Bik (Chen et al., 2004; Day et al.,
2006; Li et al., 2003; Xie et al., 2007; Zou et al., 2002) in BCICs,
we infected breast cancer cells using a pLOVE lentivirus system
as described (Blelloch et al., 2007), with the pLOVE vector
carrying the BIKDD gene or a empty control vector. Cells that
were infected with viruses carrying BIKDD significantly induced
apoptosis in MDA-MB-468 cells. Specifically, using cell number
counting, MTT and clonogenic assays, we showed that expres-
sion of BikDD significantly inhibited the growth and clonogenicity
of MDA-MB-468 cells compared with the vector control (all p <
0.01; Figure 1A). We further found that apoptotic bodies were
present in large numbers in BIKDD-infected, but not vector
control-infected cells (Figure 1B, left panel), and a high level of
cleaved PARP, which is indicative of apoptosis, was detected
in BIKDD-infected cells via immunoblotting analysis (Figure 1B,
right panel). Interestingly, expression of BikDD reduced the
CD44+/CD24 population to 29% of the control in addition to
the proapoptotic effect in total population of MDA-MB-468 cells
described above (p < 0.01; Figure 1C). Consistent with previous
studies (Gupta et al., 2009; Li et al., 2008), chemodrugs such as
paclitaxel increased this CD44+/CD24 population by 3-fold
(p < 0.01; Figure 1C). Consequently, BikDD decreased mammo-
sphere formation of MDA-MB-468 parental cells to 13%
compared with the control vector (p < 0.01; Figure 1C bottom
left). Next, we examined whether BikDD can block mammo-
sphere formation of mammosphere-selected tumor cells. We
found that BikDD expression via lentivirus infection reduced
the number of reformed mammospheres of MDA-MB-468 mam-
mosphere cells that was acquired from MDA-MB-468 parental
cells through mammosphere formation culture in vitro (p <
0.01; Figure 1D). Likewise, reduction of CD44+/CD24 popula-
tion and numbers of mammosphere formation by BikDD was
also observed in BT474 human breast cancer cells (Figure 1E).irus containing either vector alone or BIKDD, and the number of reformed
ation of BCICs. All error bars indicate standard deviation (SD).
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Figure 2. BikDD Reduces the BCICs of Patient and Mouse MMTV-Neu Primary Tumor Cells and Blocks In Vivo Tumorigenesis of
Mammosphere Cells
(A and B) Patient primary breast tumor cells were isolated from radiated-patient primary tumor after surgery, as described in experimental procedures. After
BikDD treatment, cells were subjected to FACS analysis. A total of 3000 cells were used for mammosphere formation, and mammospheres were counted with
size at >100 mm.
(C) MouseMMTV-Neu primary tumor cells were isolated from primary tumor inMMTV-Neu transgenic mouse and subjected to FACS analysis using either mouse
CD24+/CD29+ (top) or CD24+/CD49f+ (bottom) fluorescent-conjugated antibodies after BikDD treatment.
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BikDD Kills Breast Cancer Initiating CellsSimilar results were also obtained from MCF7/HER2 cell line
(data not shown).
In addition to human breast cancer cell lines, we also exam-
ined the effect of BikDD in patient and mouse MMTV-Neu trans-
genic primary breast tumor cells. First, we examined the killing
effect of BikDD in radiation-treated patient primary breast tumor
cells. As shown in Figure 2A, patient primary breast tumor cells
postradiation therapy contained 29.25% of CD44+/CD24 pop-
ulation. Under BikDD treatment, the percentage of CD44+/
CD24 population was reduced to 9.75%, i.e., 33% of the
control (or 67% inhibition, Figure 2A). BikDD also decreased
the mammosphere formation of these primary breast tumor cells
to 25% of the control (or 75% inhibition; Figure 2B). We also ob-
tained similar results from primary cell culture of another patient
breast tumor xenograft model in which patient breast tumor
specimen was directly passaged in nude mice and showed
that the CD44+/CD24 population was reduced to 49% of the
control (Figure S1A available online). In addition, we also exam-
ined the killing effect of BikDD in MMTV-Neu primary tumor cells
that were obtained from MMTV-Neu NDL2-5 transgenic mouse
(Siegel et al., 1999). We found that BikDD also significantly
reduced the percentage of either CD24+/CD29+ (Figure 2C,
top) or CD24+/CD49f+ (Figure 2C, bottom) populations, which
are biomarkers for mouse breast stem cells (Liu et al., 2007;
Shackleton et al., 2006; Stingl et al., 2006). BikDD was also
able to block the mammosphere formation of MMTV-Neu
primary tumor cells and dramatically reduced the number of
formed MMTV-Neu primary mammospheres obtained by mam-
mosphere culture (both p < 0.01; Figures 2D and 2E). Thus, these
results suggest that BikDD not only induces apoptosis in breast
cancer cell lines but also eliminates the CD44+/CD24 popula-
tion and mammospheres in primary breast cancer cells.
Next, we asked whether BikDD also inhibits cancer initiation
activity. To this end, we first selected for mammospheres from
MDA-MB-468 parental cells (referred to as ‘‘1 mammosphere
cells’’), and then the 1 mammosphere cells were infected with
lentivirus expressing BikDD or vector control. Two days after
infection, the survived cells were trypsinized, counted, and in-
jected into NOD/SCID mice with the indicated numbers of cells
(Group B). In this experiment, only 500 1 mammosphere cells
were sufficient to induce tumor formation (Figure 2F). In contrast,
the 1 mammosphere cells survived after BikDD treatment
exhibited a significant reduction in tumorigenicity (GroupB), sug-
gesting that BikDD treatment reduced the BCIC population. To
ensure this phenomenon can be observed in the secondary
transplants (Al-Hajj et al., 2003; Dick, 2003; Haase et al., 1995;
Lapidot et al., 1996), we harvested the tumor tissues from the
vector-control group (because virtually no tumor was developed
in the BikDD-treated group) to isolate primary tumor cells, and
selected for mammospheres (referred to as ‘‘2 mammosphere
cells’’). Again, these 2 mammosphere cells were infected with
lentivirus expressing BikDD or vector-control. Two days after(D) For mammosphere formation, 5000 cells were used and mammospheres we
(E) MMTV-Neu primary mammospheres were treated with either vector alone or
mation. Scale bar indicates 50 mm.
(F) Indicated numbers of parental MDA-MB-468 cells and mammosphere cells w
NOD/SCID mice, and mice were monitored for the next months for tumorigenes
Caninfection, the survived cells were trypsinized, separated into
single-cell suspension, counted, and then injected into NOD/
SCID mice with indicated numbers of cells (Group C). As shown
in Figure 2F, these 2 mammosphere cells from the vector-
control group still maintained their ability to induce tumor in
mice with only 500 cells. However, the 2 mammosphere cells
survived after BikDD treatment no longer produced tumor
(Group C). Together, these results suggest that the selected
mammosphere cells maintained their cancer initiation activity
by secondary transplants (vector-control group), and BikDD
expression in those selected mammosphere cells significantly
inhibited their cancer initiation activity, most likely by reduction
of BCIC population.
Furthermore, in order to address whether BikDD can inhibit
cancer initiation activity during an in vivo tumorigenicity assay,
we adopted a gene therapy protocol (see below), which allows
us to assay the cancer initiation activity from tumor xenografts
growing in mice after BikDD treatment. To this end, we treated
mice bearing MDA-MB-468 tumor xenografts with control
vector-liposome or VISA-claudin4-BikDD-liposome complexes.
After treatment stopped, we harvested tumor tissues from
mice, created a single-cell suspension, and then passaged
them into new animals with indicated numbers of cells (Fig-
ure S1B). We found tumor cells from mice treated with VISA-
claudin4-BikDD-liposome complexes also demonstrated signif-
icantly reduced tumorigenesis in new animals compared to
that frommice treated with vector-control-liposome complexes.
Specifically, no mice developed tumor in BikDD-treated groups
that received 104 and 105 cells isolated from tumor of the
VISA-claudin4-BikDD-treated mice (Figure S1B). In addition,
we also observed a reduction in CD44+/CD24 population
and the number of mammosphere formed upon in vivo VISA-
claudin4-BikDD treatment (Figures S1C and S1D). Taken
together, these results indicate that BikDD indeed eliminates
BCICs under a gene therapy setting.
Co-Silencing of Multiple Bcl-2 Antiapoptotic Members
Mimics the Proapoptotic Effect of BikDD in BCICs
In our previous work, BikDD was shown to have enhanced
binding affinity to Bcl-2 antiapoptotic proteins such as Bcl-2
and Bcl-xL compared with the wild-type Bik (Li et al., 2003).
Therefore, we examined the effect of its major binding partners
including Bcl-2, Bcl-xL, and Mcl-1 in BCICs using an shRNA
knockdown approach. Interestingly, co-silencing Bcl-2, Bcl-xL,
and Mcl-1 reduced the CD44+/CD24 population to 25% of
the control MDA-MB-468 cells (Figure 3A) and consequently
decreased mammosphere formation of MDA-MB-468 cells
to 10% of the control (Figure 3B). However, we found that indi-
vidual knockdown of each of the three molecules only had
a partial killing effect in CD44+/CD24 population and mammo-
spheres, suggesting that Bcl-2 antiapoptotic proteins may have
functional redundancy in the BCIC survival (Figures 3A and 3B).re counted with size >100 mm.
BikDD via lentivirus infection, and mammospheres were counted after refor-
ith or without BikDD treatment, were inoculated into the mammary fat pad of
is. All error bars indicate SD. See also Figure S1.
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Figure 3. Co-Silencing of Multiple Bcl-2 Antiapoptotic Proteins Mimics the Proapoptotic Effect of BikDD in BCICs
(A) MDA-MB-468 cells were infectedwith lentivirus containingBIKDD or shRNAs against scramble,BCL-2,BCL-xL,MCL-1, or all of them, respectively. Cells from
each group were analyzed by flow cytometry 7 days post virus infection.
(B) Indicated numbers of cells were subjected to mammosphere culture post infection up to 2 weeks.
(C) The protein expression levels of Bcl-2, Bcl-xL, Mcl-1, and tubulin were detected 7 days after virus infection. All error bars indicate SD. See also Figure S2.
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BikDD Kills Breast Cancer Initiating CellsWhen BikDD was expressed by infection in these cells as
described above (Figures 1A and 1B), we showed that it reduced
CD44+/CD24 population and mammosphere formation to 27%
and 10%, respectively, compared with vector control group,
which is comparable to the killing effect of co-silencing its three
major binding partners Bcl-2, Bcl-xL, and Mcl-1. Furthermore,
BikDD did not enhance the killing effect against BCICs post
co-silencing of all three molecules (Figure S2). The specificity
of shRNAs against these three molecules was validated by
immunoblotting (Figure 3C), supporting that the reduction in
CD44+/CD24 population and number of mammospheres
were indeed due to the loss of these protein expression. Similar
results were also obtained from another set of shRNAs against
these three antiapoptotic Bcl-2 family proteins (see Supple-
mental Information and also data not shown), in order to exclude
the off-target issue of shRNAs. We also carried out the same
experiment in BT474 cells and showed similar results to that of
MDA-MB-468 described above (data not shown). Taken
together, we determined that efficient induction of apoptosis in346 Cancer Cell 20, 341–356, September 13, 2011 ª2011 Elsevier InBCICs requires silencing of all three antiapoptotic Bcl-2 proteins,
which suggests that co-antagonism of multiple Bcl-2 antiapop-
totic proteins by BikDD may have a better killing effect against
BCICs than targeting individual antiapoptotic proteins, which is
likely due to their functional redundancy in the survival of BCICs.
The Engineered VISA-Claudin-4 Promoter Is Robustly
and Selectively Activated in Breast Cancer Cells In Vitro
and In Vivo
To explore BikDD gene therapy, we searched for an expression
vector that allows BIKDD gene to be selectively expressed in
breast cancer cells. In our previous work, we developed a tran-
scriptional targeting vector ‘‘VISA’’ (VP16-GAL4-WPRE inte-
grated systemic amplifier) based on an engineered expression
vector, which can enhance a cancer-specific promoter activity
by several hundred-fold and prolong duration of gene expression
without loss of its cancer specificity. This system has been
successfully applied in pancreatic, lung, and ovarian cancer
preclinical models (Sher et al., 2009; Xie et al., 2007; 2009). Inc.
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Figure 4. The Engineered VISA-Claudin4-Luc Is Robustly and Selectively Expressed in Breast Cancer Cells In Vitro and In Vivo
(A) The claudin-4 promoter is selectively activated in breast cancer cell lines.
(B) Schematic diagram of engineered claudin-4-based constructs.
(C) The promoter activity of engineered VISA-claudin4-Luc is robust and selectively activated in breast cancer cell lines in vitro.
(D) The promoter activity of VISA-claudin4-Luc is much longer than that of CMV promoter in breast cell lines. The ratio of VISA-claudin4-Luc/CMV-Luc at day 2
and day 5 is shown.
(E) The engineered VISA-claudin4-Luc was robust and selectively expressed in tumor in vivo. Mice were subjected to luciferase imaging 48 hr after injection with
2.5 mg/kg DNA plasmid per mice in 100 ml plasmid/liposome complex, 5 mice per group. The photon signals were quantified, and the percentage of the photon
signals as compared with the CMV-Luc (setting at 100%) was presented.
(F) Mice from (E) were dissected, and tumor tissue and other specified organs were removed out and subjected to ex vivo imaging. All error bars indicate SD. See
also Figure S3.
Cancer Cell
BikDD Kills Breast Cancer Initiating Cellsthis study, we also utilized this powerful targeting approach to
express BikDD in breast cancer cells under a promoter that is
activated in breast cancer cells.
By comparing the mRNA expression level between breast
cancer and normal tissues in the public SAGE and cDNA micro-
array libraries, we identified several candidate promoters
including claudin-4, fatty acid synthase (FASN), MMP1, and
StarD10 (Figure S3A). After comparing their promoter activities
in multiple breast cancer cell lines, we found that the claudin-4
promoter exhibited highest activity among all other promotersCantested. Moreover, this promoter had little activity in normal cell
lines and several cancer types (Figure 4A), suggesting its selec-
tivity for breast cancer.
Although the claudin-4 promoter was selectively expressed in
breast cancer cells, its activity level was only 1%–4% of CMV
promoter activity (Figure S3B). Therefore, we integrated the
claudin-4 promoter into the VISA system (Figure 4B). Indeed,
the engineered VISA-claudin4-Luc vector showed robust lucif-
erase activity in almost all of the 13 breast cancer cell lines tested
and was comparable to or higher than that of the CMV promotercer Cell 20, 341–356, September 13, 2011 ª2011 Elsevier Inc. 347
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BikDD Kills Breast Cancer Initiating Cells(Figure 4C). In addition, its activity was nearly silent in normal cell
lines compared with that of the CMV promoter (Figure 4C), which
further supports its breast cancer selectivity. Moreover, the
expression ratio of luciferase from VISA-claudin4-Luc to CMV-
Luc at day 5 was consistently higher than at day 2 in the five
breast cancer cell lines tested (Figure 4D), suggesting that the
prolonged duration of gene expression from the VISA vector
was likely due to the presence of WPRE, an RNA stabilizing
element, in the VISA system as reported previously (Xie et al.,
2007).
To further examine the breast cancer-specific expression
in vivo, we treated mice with CMV-Luc or VISA-claudin4-Luc
plus DOTAP/Cholesterol liposome as the gene delivery system
via tail vein injection at a single dose of 2.5 mg/kg in 4T1
tumor-bearing syngeneic mice (Templeton et al., 1997; Xie
et al., 2007). The mammary tumors were inoculated in the fourth
inguinal mammary gland to prevent overlapping signals from
lung and heart in which CMV promoter was highly activated.
We found that the luciferase activity of VISA-claudin4-Luc was
selectively localized in the tumor region, whereas the CMV-Luc
activity was primarily observed in the lung with weak signals in
the tumor area after 48 hr (Figure 4E). This result was further
confirmed by examining these individual organs, which demon-
strated that the signal of VISA-claudin4-Luc was indeed from the
tumor itself and not from other organs (Figure 4F). Collectively,
we conclude that the VISA-claudin4-Luc vector is robustly and
selectively expressed in breast cancer cells both in vitro and
in vivo.
The VISA-Claudin4-BikDD Expression Efficiently
Inhibits Breast Cancer Cells Growth In Vitro
and In Vivo and Has Less Toxicity than CMV-BikDD
To investigate the therapeutic efficacy of BikDD, we incorpo-
ratedBIKDD into VISA-claudin4 vector (Figure 5A) and examined
its inhibitory effect on cell growth in a panel of breast cancer and
normal cell lines. Compared with CMV-BikDD, VISA-claudin4-
BikDD demonstrated comparable or stronger inhibitory effects
on cell growth of different breast cancer cell lines (Figure 5B).
In contrast, it had virtually little or no effect on the growth of
human normal cell lines MCF10A, 184A1, and WI38 (Figure 5B).
This killing effect was unlikely a result of nontherapeutic compo-
nent of the VISA system such as GAL4/VP2 synthetic transcrip-
tion factor because VISA-claudin4-Luc has virtually no effect on
the growth of breast cancer cells (Figure 4C and data not shown).
Thus, VISA-claudin4-BikDD efficiently and selectively killed
breast cancer cells in vitro, consistent with the luciferase expres-
sion data (Figure 4C).
To evaluate the antitumor efficacy of VISA-claudin4-BikDD
in vivo, we tested one syngeneic mouse breast tumor and
multiple human breast tumor orthotopic xenograft models. First,
we used the 4T1-Luc syngeneic mouse mammary orthotopic(C-D) VISA-claudin4-BikDD greatly suppressed tumor growth and disseminatio
0.75 mg/kg VISA-claudin4-BikDD or CMV-BikDD as indicated by arrows, respec
(E) Mice survival was monitored after 28 days posttumor transplantation.
(F) VISA-claudin4-BikDD at 0.75 mg/kg significantly reduced the tumor growth o
(G) Mice survival was monitored after 60 days posttumor transplantation.
(H) VISA-Claudin4-BikDD is much safer than CMV-BikDD with intravenous treatm
Figure S4.
Canmodel and found that both CMV-BikDD and VISA-claudin4-
BikDD, at 0.75 mg/kg, twice per week for 3 weeks, greatly
reduced 4T1 tumor growth and prolonged mouse survival in vivo
(Figures 5C–5E; both p < 0.01). Consistently, both CMV-BikDD
and VISA-claudin4-BikDD effectively reduced tumor growth
and prolonged mice survival in a human breast orthotopic
xenograft model (Figures 5F and 5G; both p < 0.01). Notably,
VISA-claudin4-BikDD suppressed tumor growth and prolonged
mice survival more significantly than CMV-BikDD (Figures 5D,
5F, and 5G; all p < 0.05).
Similar results were also obtained from other breast cancer
orthotopic models such as MCF7/HER2, BT474, and MDA-
MB-468 (see below). In addition, expression of BikDD mRNA
containing the WPRE RNA stabilizing element is readily detect-
able and can be distinguished from endogenous wild-type Bik
in tumor tissues of MCF7/HER2 and BT474 xenograft models
after VISA-claudin4-BikDD treatment but not in untreated mice
(data not shown), confirming the presence of the therapeutic
gene in the tumors after treatment. We also found that VISA-
claudin4-BikDD produced less toxicity compared with CMV-
BikDD in vivo (Figure 5H) without obvious changes in AST,
ALT, and BUN as determined by liver and kidney functional
assays, respectively (Figure S4). These results indicate that
VISA-claudin4-BikDD efficiently inhibited tumor growth of breast
cancer xenografts in vivo.
The VISA-Claudin4-BikDD Synergizes with Lapatinib
in EGFR+/HER2+ Breast Cancer Cell Lines In Vitro
and In Vivo
As previously reported, the clinical efficacy of anti-HER2 agents
such as lapatinib and trastuzumab are greatly limited by either
inoperative apoptosismachinery or overexpression of Bcl-2 anti-
apoptotic proteins following lapatinib treatment that may be
improved by inactivation of Bcl-2 antiapoptotic proteins (Burris
et al., 2005; Martin et al., 2008; Mohsin et al., 2005; Xia et al.,
2006). Therefore, we examined whether BikDD or inhibition of
Bcl-2 antiapoptotic members could enhance the therapeutic
effect of lapatinib in breast cancer cells. In this study, we found
that VISA-claudin4-BikDD effectively sensitized BT474 and
MDA-MB-453 (HER2+), and MDA-MB-468 and BT20 (EGFR+)
cells to lapatinib (Figure 6A, see also Figures S5A and S5B
for EGFR/HER2 expression and combination index). It should
be mentioned that there was virtually no added killing effect
under the combination of VISA-claudin4-BikDD plus lapatinib
in the EGFR-/HER2 MCF7 human breast cancer cell line or in
MCF10A normal human mammary epithelial cell line (Figure 6A).
The lack of sensitization of VISA-claudin4-BikDD to lapatinib in
MCF7 is most likely due to low expression of EGFR and HER2
(Figure S5A) whereas the lack of activity in the normal cell lines
is most likely due to the absence of VISA-claudin4 expression
activity in normal cells (Figure 4C). Moreover, we determinedn of 4T1 mouse breast orthotopic synergic tumors. Mice were injected with
tively.
f MDA-MB-435 human breast cancer orthotopic xenograft in nude mice.
ent of 5 mg/kg plasmid/liposome complex. All error bars indicate SD. See also
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Cancer Cell
BikDD Kills Breast Cancer Initiating Cellsthat this is not a result of low transfection efficiencies because all
cell lines tested using the electroporation method had similar
GFP expression level (data not shown).
We further examined whether inactivation of Bcl-2 antiapop-
totic proteins by siRNAs sensitized EGFR+/HER2+ breast cancer
cells to lapatinib. We found that co-silencing of Bcl-2, Bcl-xL,
and Mcl-1 indeed sensitized EGFR+/HER2+ breast cancer cells
to lapatinib that was comparable to BikDD alone, which sur-
passed individual knockdown of them (Figure 6B, top) but not
in EGFR/HER2 MCF7 cell line (Figure 6B, bottom left). How-
ever, when HER2 was expressed in the MCF7 cells (Wang
et al., 2004), co-silencing of these three Bcl-2 antiapoptotic
members was able to sensitize the cells to lapatinib again (Fig-
ure 6B, bottom right), suggesting that co-antagonism of Bcl-2,
Bcl-xL, and Mcl-1 by three specific siRNAs or BikDD alone can
overcome the functional redundancy of Bcl-2 antiapoptotic
proteins and synergized with lapatinib.
The sensitization effect of VISA-claudin4-BikDD plus lapatinib
treatment was further supported by the enhanced expression
level of cleaved PARP (a major apoptosis signal) under combina-
tional therapy. Combination treatment of VISA-claudin4-BikDD
plus lapatinib enhanced the expression level of cleaved PARP
in HER2+ MCF7/HER2 and EGFR+ MDA-MB-468 cells to about
44.9% or 162.8% more than either single treatment alone using
both VISA-claudin4-Luc and pUK21 plasmid as negative
controls (Figure S5C). These results suggest that the enhanced
proapoptotic effect under a combination of VISA-claudin4-
BikDD plus lapatinib may contribute to their synergistic effects
on the growth of EGFR+/HER2+ breast cancer cells.
To further examine the therapeutic efficacy of VISA-claudin4-
BikDD plus lapatinib combination in vivo, we treated mice
bearing HER2+ BT474 human breast cancer xenografts with
VISA-claudin4-BikDD and/or lapatinib. Lapatinib was adminis-
tered orally at a dose of 50 mg/kg every other day, and VISA-
claudin4-BikDD was intravenously injected as indicated by
arrows in Figure 6C. VISA-claudin4-BikDD or lapatinib alone
significantly inhibited tumor growth compared with the vector
alone group (Figure 6C; both p < 0.05). However, the combina-
tion treatment of VISA-claudin4-BikDD plus lapatinib demon-
strated even much better therapeutic efficacy than single-agent
treatment of either VISA-claudin4-BikDD or lapatinib alone
(Figure 6C; both p < 0.05). A more significant synergy between
VISA-claudin4-BikDD and lapatinib was observed when MDA-
MB-468 cells was transfected by VISA-claudin4-BikDD once
before transplanted into nude mice, followed by lapatinib treat-
ment every other day (p < 0.01, Figure S5D). Similar results
were also obtained from EGFR+ MDA-MB-468 orthotopic xeno-
graft model and HER2+ MCF7/HER2 human breast cancerFigure 6. VISA-Claudin4-BikDD Has Synergistic Effects with Lapatinib
Protein
(A) VISA-claudin4-BikDD at 0.5 mg sensitized multiple EGFR+/HER2+ breast cance
cell line and the MCF10A normal breast cell line. The percentage of the cell viab
presented.
(B) Cancer cells were transiently transfected with siRNAs againstBCL-2,BCL-xL,
concentrations for 72 hr, and the OD570nm was measured 4 hr after MTT staining
(C) VISA-claudin4-BikDD has synergistic effects with lapatinib in multiple huma
claudin4-BikDD-liposome complexes intravenously as indicated by arrows. Lapat
SD. See also Figure S5.
Canorthotopic xenograft model (Figure 6C; both p < 0.05). Thus, tar-
geted expression of VISA-claudin4-BikDD sensitized breast
cancer cells to lapatinib in vitro and in vivo and provided addi-
tional benefit when combined with lapatinib, ensures that normal
cells or tissues are spared from its potent proapoptotic effect.
In addition, we also explored whether VISA-claudin4-BikDD
can sensitize breast cancer cells to other clinical used drugs
because Bcl-2 antiapoptotic proteins have been shown to
contribute to the development of drug resistance following
chemotherapy (Ellis et al., 1998; Oltersdorf et al., 2005; Tabuchi
et al., 2009). Among them, we found that VISA-claudin4-BikDD
also sensitized multiple breast cancer cell lines to paclitaxel
in vitro including the EGFR/HER2MCF7 human breast cancer
cell line (Figure S5E). However, it should be mentioned that
BikDD sensitized the HER2+ SKBr3 human breast cancer cell
line to lapatinib but not paclitaxel (data not shown), suggesting
that the combination of VISA-claudin4-BikDD plus lapatinib
may have potential benefits in EGFR+ or HER2+ breast cancer
cells whereas the combination of VISA-claudin4-BikDD plus
paclitaxel may be more useful for EGFR/HER2 breast cancer
cells.
VISA-Claudin4-BikDD Treatment Efficiently Reduces
CD44+/CD24– Population Even After Paclitaxel
Treatment and Markedly Attenuates Tumor Growth
at Off-Therapy Stage
Next, we examined the activity of engineered VISA-claudin4
promoter in BCICs. To determine if VISA-claudin4 vector could
drive gene expression in BCICs, we used VISA-claudin4-Luc to
measure its promoter activity. As shown in Figure 7A, luciferase
expression of VISA-claudin4-Luc in the CD44+/CD24 popula-
tion and mammospheres cells of MDA-MB-468, MCF7/HER2,
MDA-MB-435, BT549, and HBL100 breast cancer cell lines
was comparable or even higher compared with the total
population, indicating the engineered claudin4 promoter is acti-
vated in BCICs, even in claudin-low cell lines (Figure S6). Next,
we examined the therapeutic effect of BikDD in MDA-MB-
468 tumor orthotopic xenograft mouse model. MDA-MB-468
tumor-bearing mice were treated with empty vector, lapatinib,
paclitaxel, VISA-claudin4-BikDD, and VISA-claudin4-BikDD
plus lapatinib or paclitaxel. Consistent with the in vitro data,
BikDD treatment significantly reduced the percentage of
CD44+/CD24 population of MDA-MB-468 tumor to 48% com-
pared to vector control (set as 100%) whereas paclitaxel treat-
ment increased this population by 3-fold as expected at day
26 of last treatment (both p < 0.05; Figure 7B). Interestingly,
BikDD blocked the expansion of the CD44+/CD24 population
under paclitaxel treatment (p < 0.01; Figure 7B). A reduction inin Breast Cancer Cells through Antagonism of Bcl-2 Antiapoptotic
r cell lines to 1 mM lapatinib, but not in the EGFR/HER2MCF7 breast cancer
ility as compared with itself without lapatinib treatment (setting at 100%) was
MCL-1, or all of them, respectively, and were subjected to lapatinib at indicated
.
n breast xenograft mouse models. Mice were treated with 0.75 mg/kg VISA-
inib was orally administrated at 50mg/kg every other day. All error bars indicate
cer Cell 20, 341–356, September 13, 2011 ª2011 Elsevier Inc. 351
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Figure 7. VISA-Claudin4-Luc Is Activated in BCICs, and BikDD Treatment Efficiently Reduces the CD44+/CD24– Population of MDA-MB-468
Mammosphere-Induced Tumors in Mice
(A) BCICs from MDA-MB-468, MCF7/HER2, MDA-MB-435, BT549, and HBL100 cells, isolated by either FACS sorting or mammosphere culture, were transient
transfectedwith VISA-claudin4-Luc, with pRL-TK as internal control. The luciferase signal wasmeasured in each population of unsorted parental cells andBCICs,
normalized to the DNA concentration of firefly/Renilla luciferase to exclude the potential different transfection rate. The percentage of the luciferase signals as
compared with unsorted total population (setting at 100%) was presented.
(B) The CD44+/CD24 population of MDA-MB-468 tumor in the different groups were determined at Day 26 (the day of last drug treatment). The p values shown
were obtained by comparison with the control group.
(C and D) For off-therapy study, we monitored tumor growth in different group after treatment stopped at day 26 post first drug treatment, and the tumor growth
rate (slope) of off-therapy stage (day 26 to day 49) was calculated by exponential trendline in Excel software (D). All error bars indicate SD. See also Figure S6.
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BikDD Kills Breast Cancer Initiating Cellsthe CD44+/CD24 population in VISA-claudin4-BikDD or VISA-
claudin4-BikDD plus paclitaxel at day 26 led to significant tumor
growth inhibition compared with paclitaxel alone after drug
cessation from day 26 to day 49 (off-therapy stage) with a growth
rate ratio determined from the relative slope of the tumor growth
curves of 0.44, 0.45, and 1.45, respectively (Figures 7C and 7D).
The relative slopes were determined by measuring the slope of
tumor growth curves in each group during the off-therapy stage
from day 26 to day 49 (calculated from the exponential trendlines
inMicrosoft Excel) compared to control vector (Figure 7D). Forty-
nine days after first drug treatment, VISA-claudin4-BikDD plus
paclitaxel exhibited better tumor growth suppression compared
with VISA-claudin4-BikDD alone (p < 0.05; Figure 7C left). We352 Cancer Cell 20, 341–356, September 13, 2011 ª2011 Elsevier Inalso found similar results from combination treatment of VISA-
claudin4-BikDD and lapatinib (Figures 7B–7D). Collectively,
these results indicate that BikDD driven by VISA-claudin4 vector
potently reduced the CD44+/CD24 population in vivo even after
chemotherapy and efficiently attenuated tumor growth after
cessation of drug treatment, suggesting that VISA-claudin4-
BikDD treatment may serve as a potential therapeutic approach
to kill BCICs, which is considered as a major barrier for breast
cancer treatment.
Taken together, the current study suggests a potential thera-
peutic approach for breast cancer treatment by showing: (1),
BikDD effectively reduced BCICs through co-antagonism of its
major binding partners Bcl-2 antiapoptotic proteins; (2), thec.
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breast cancer cells including BCICs; and (3), targeted expression
of BikDD driven by VISA-claudin4 vector demonstrated potent
antitumor activities in multiple syngeneic and orthotopic mouse
models, synergized with lapatinib and paclitaxel, and attenuated
tumor growth at off-therapy stage by reducing BCICs. Therefore,
it is worthy of moving VISA-claudin4-BikDD into a clinical trial,
which will provide potential benefit in breast cancer patients by
triggering apoptosis in both non-BCICs and BCICs.
DISCUSSION
There is increasing evidence to support that conventional cancer
therapies that are able to kill the bulk of differentiated cancer
cells within tumors have failed to eliminate cancer initiating cells
(Gupta et al., 2009; Park et al., 2009). Residual cancer cells such
as BCICs will reform new tumor and eventually lead to tumor
relapse in patients. At present, there are no effective treatments
available for treating BCICs in the clinic, which are urgently
needed for relapsed breast cancer patients. However, it is worth
mentioning that Gupta et al. (2009) recently identified a com-
pound that can specifically kill BCICs. Thus, agents that can
target BCICs are worthy of moving into clinical trials.
In this study, we found that antiapoptotic Bcl-2 family of
proteins play an important role in maintaining survival of BCICs,
and elimination of these chemo-resistant cancer initiating cells
required co-antagonism of Bcl-2 antiapoptotic proteins either
through BikDD expression or co-silencing of Bcl-2, Bcl-xL and
Mcl-1 (Figure 1, Figure 2, and Figure 3). We have provided
evidence to show that co-antagonism of Bcl-2 antiapoptotic
proteins via BikDD not only markedly reduced BCICs, but also
effectively killed non-BCICs in multiple breast cancer cell lines,
which surpassed knockdown of them individually. Because
multiple Bcl-2 antiapoptotic members are redundantly and
highly expressed in several breast cancer cell lines including
BT474 and MDA-MB-468 (Figure S5A), this could explain why
co-antagonism of Bcl-2 antiapoptotic proteins had better
therapeutic effect than inhibition of them individually. Inhibition
of the CD44+/CD24 population and mammosphere formation
by BikDD expression in patient and mouse primary tumor cells
suggests its potential clinical therapeutic value. Moreover, the
killing effect of BikDD against BCICs is likely mediated through
co-inhibition of the three major binding partners Bcl-2, Bcl-xL,
and Mcl-1 because BikDD did not further enhance the killing
effect against BCICs post co-silencing of these three molecules
that were validated in both MDA-MB-468 and BT474 cell lines
(Figure S2).
Practically, it would be advantageous to develop a breast
cancer therapy that can target breast cancer cells including
BCICs through inhibition of antiapoptotic Bcl-2 family of
proteins. To this end, we engineered a breast cancer targeting
VISA-claudin4 vector to express the therapeutic gene selectively
in breast cancer cells including BCICs. Although claudin-4
protein were reported to be expressed in breast tissue during
lactation and other cancer types (Hewitt et al., 2006), the expres-
sion level of claudin-4 was significantly lower in breast normal
tissues compared to breast cancer according to the data
obtained from the public SAGE and microarray database
(70:1200 ratio), which was further supported by other studiesCan(Kominsky et al., 2004; Soini, 2004). In addition, we also exam-
ined its promoter activity in claudin-low cell lines that have
been shown to correlate with BCICs (Hennessy et al., 2009;
Kuo et al., 2009; Neve et al., 2006). This 1100-bp truncated frag-
ment of claudin-4 promoter, which was originally cloned from
claudin-low MDA-MB-435 cells, exhibited comparable or higher
activity in claudin-low subtype compared with luminal and basal
A subtypes, with little expression in normal breast cancer cell
lines (Figure S6). Moreover, it still processed comparable
promoter activities in the CD44+/CD24 population and mam-
mosphere cells compared with parental cells after constructing
it into the VISA system even in the claudin-low subtype breast
cancer cell lines (Figure 7A), suggesting that this region of the
claudin-4 promoter is an excellent candidate for transcription-
ally-targeted breast cancer therapy.
Next, we demonstrate significant antitumor activities of VISA-
claudin4-BikDD in a mouse syngeneic and multiple human
orthotopic xenograft breast cancer models in vitro and in vivo
(Figures 5C–5G, and Figure 6C), which strongly suggest its feasi-
bility for breast cancer treatment. For breast cancer treatment,
anti-HER2 drugs such as lapatinib and trastuzumab have been
widely used in HER2+ breast cancer patients (Geyer et al.,
2006; Li et al., 2008). However, their clinical efficacy appeared
to be limited by inoperative apoptotic machinery or overexpres-
sion antiapoptotic members of Bcl-2 family proteins after drug
treatment (Martin et al., 2008; Xia et al., 2006). Indeed, BikDD
sensitized HER2+ breast cancer cells to lapatinib, which was
mimicked by co-inhibition of antiapoptotic Bcl-2 family proteins
by three combined siRNAs but not individually. Moreover, BikDD
also sensitized EGFR+ breast cancer cells to lapatinib, which has
been reported to be less effective under lapatinib treatment
compared with HER2+ cells (Konecny et al., 2006). In addition to
that, we also found that BikDD can sensitize multiple breast
cancer cell lines topaclitaxel includingEGFR/HER2MCF7cells
(Figure S5E), suggesting that the combination of VISA-claudin4-
BikDD plus paclitaxel may provide some benefits in EGFR/
HER2 breast cancer cells. Thus, the evidence shown here
greatly supports our notion that apoptosis-promoting agents
like BikDD delivered by the VISA-claudin4-vector would be
expected to provide additional therapeutic benefits to lapatinib
treatment inEGFR+/HER2+breastcancercells andmaybepoten-
tially used for EGFR+/HER2+ breast cancer patients following our
pancreatic VISA-based targeting vector (Xie et al., 2007), which is
in the process of being moved into human clinical trials.
Moreover, we demonstrated that the engineered VISA-
claudin4 promoter was activated in the CD44+/CD24 popula-
tion and mammosphere cells (Figure 7A) (Casagrande et al.,
2011). BikDD treatment not only reduced the BCIC population
of MDA-MB-468 in vitro and in vivo but also blocked the
CD44+/CD24 population expansion under paclitaxel treatment
whereas paclitaxel alone greatly enhanced this population after
drug treatment (Figure 1C and Figure 7B). Of note, BikDD was
also able to reduce the CD44+/CD24 population and mammo-
sphere formation in radiation-treated patient breast tumor cells
(Figures 2A and 2B). Reduction of CD44+/CD24 population by
BikDD or its combination with paclitaxel or lapatinib greatly
attenuated tumor growth at off-therapy stage from day 26 to
day 49 post first drug treatment (Figures 7C and 7D). These
results strongly suggest that BikDD can eliminate BCICs, evencer Cell 20, 341–356, September 13, 2011 ª2011 Elsevier Inc. 353
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may provide an effective strategy to inhibit breast tumor growth
including BCICs.
In summary, our study uncovered the important role of Bcl-2
antiapoptotic proteins in the survival of BCICs, and coinactiva-
tion of antiapoptotic Bcl-2 family proteins is required to reduce
BCICs and sensitize EGFR+/HER2+ breast cancer cells to lapa-
tinib, suggesting a potential therapeutic strategy targeting
BCICs. As it has been shown that non-BCICs can also transit
into BCICs at a significant rate under certain condition (Gupta
et al., 2009), it would be advantageous to develop such a thera-
peutic agent that can target both population of breast cancer
cells. By using our newly developed VISA-claudin4-BikDD for
treating breast cancer, it is likely that therapeutic efficacy will
be enhanced and potential side effects prevented as we have
shown that BikDD targets both non-BCICs and BCICs and
demonstrates virtually no toxicity in normal cells.
EXPERIMENTAL PROCEDURES
Patient Primary Tumor Specimen
Patient breast tumor specimen was collected within 1 hr after surgery under
the guidelines approved by the Institutional Review Board at M.D. Anderson
Cancer Center, and written informed consent was obtained from patients in
all cases at time of enrollment. The tumors were minced into small pieces,
and were digested by collagenase/hyaluronidase for 3–16 hr (Stemcell; no.
07912). Cells were further cultured in Matrigel-coated 6-well plate using
MEGM complete medium (Lonza/Clonetics; no. cc-3051).
In Vivo Mouse Models
All animal procedures were conducted under the guidelines approved by the
Institutional Animal Care and Use Committee (IACUC) at M.D. Anderson
Cancer Center. Female BALB/cA normal and athymic mice (Harlan Laborato-
ries, Houston, TX) were used as hosts for tumor xenografts. Mice were divided
according to the mean value of tumor volume or photon signals in each group.
For MCF7/HER2 and BT474 cell lines, 17b-estradiol with biodegradable
carrier-binder (Innovative Research of America, Sarasota, FL) was inoculated
under the mice skin 3 days before tumor injection. Lapatinib was administered
orally at 50mg/kg every other day (Scaltriti et al., 2007). Paclitaxel was injected
intravenously at 3 mg/kg every other day. VISA-claudin4-BikDD plus liposome
mixture was injected intravenously at 0.75 mg/kg as indicated by arrows in the
figures. Tumor was measured twice weekly with a caliper, and tumor volume
was calculated by the formula: p/6 3 length 3 width2.
Statistical Analyses
Data were analyzed by the Student’s t test except Cox-Mantel test on survival
rates using Statistica 6.0 software. The remaining experimental procedures
can be found in Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, six figures and can be found with this article online
at doi:10.1016/j.ccr.2011.07.017.
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